| 31.10 14:43 | dpa-AFX: *BRISTOL MYERS SQUIBB +6,5% NACH ANGEHOBENER GEWINNPROGNOSE |
| 31.10 12:57 | dpa-AFX: ROUNDUP: Bristol Myers Squibb Lifts FY24 Earnings View Above Market; Stock Up In Pre-market |
| 31.10 12:24 | dpa-AFX: Bristol-Myers Squibb Co. Q3 Profit Decreases, But Beats Estimates |
| 31.10 12:10 | dpa-AFX: *BRISTOL MYERS SQUIBB NOW EXPECTS FY REVENUES GROWTH TO BE 5% VS. PRIOR OUTLOOK UPPER END OF LOW SINGLE-DIGIT RANGE |
| 31.10 12:09 | dpa-AFX: *BRISTOL MYERS SQUIBB NOW EXPECTS FY EPS TO BE $0.75 - $0.95 VS. PRIOR OUTLOOK OF $0.60 - $0.90 |
| 31.10 12:08 | dpa-AFX: *BRISTOL MYERS SQUIBB Q3 ATTRIBUTABLE NET INCOME $1.2 BLN OR $0.60/SHR VS. $1.9 BLN OR $0.93/SHR PRIOR YEAR |
| 31.10 12:07 | dpa-AFX: *BRISTOL MYERS SQUIBB Q3 NON-GAAP EPS $1.80 VS. $2.00 PRIOR YEAR |
| 31.10 12:04 | dpa-AFX: *BRISTOL MYERS SQUIBB Q3 REVENUES $11.9 BLN, INCREASE OF 8% OR 10% ON ADJUSTED BASIS |
| 31.10 12:03 | dpa-AFX: *BRISTOL MYERS SQUIBB Q3 GAAP EPS $0.60 AND NON-GAAP EPS $1.80 |
| 31.10 12:01 | dpa-AFX: Bristol-Myers Squibb Q3 24 Earnings Conference Call At 8:00 AM ET |
| 23.10 08:41 | Evotec erweitert Partnerschaft mit Bristol Myers Squibb - Aktie steigt |
| 23.10 07:48 | dpa-AFX: Evotec erhält 50 Millionen US-Dollar aus Kooperation mit Bristol Myers Squibb |
| 23.10 07:48 | Evotec erhält 50 Millionen US-Dollar aus Kooperation mit Bristol Myers Squibb |
| 23.10 07:43 | dpa-AFX: Evotec erhält 50 Millionen US-Dollar aus Kooperation mit Bristol Myers Squibb |
| 23.10 07:30 | dpa-AFX: *EVOTEC ERHÄLT EINE ZAHLUNG VON 50 MIO USD |
| 23.10 07:30 | dpa-AFX: *EVOTEC: EVOTEC UND BRISTOL MYERS SQUIBB ERWEITERN PROTEOMICS-PARTNERSCHAFT |
| 17.10 09:33 | dpa-AFX: *BERNSTEIN STARTET BRISTOL-MYERS SQUIBB MIT 'MARKET-PERFORM' - ZIEL 56 USD |
| 17.10 09:33 | dpa-AFX: *BERNSTEIN STARTS BRISTOL-MYERS SQUIBB WITH 'MARKET-PERFORM' - PRICE TARGET 56 USD |
| 30.09 14:02 | dpa-AFX: Prime Medicine Inks Strategic Research Collaboration And License Agreement With Bristol Myers Squibb |
| 30.09 13:43 | dpa-AFX: *PRIME MEDICINE, BRISTOL MYERS TO DEVELOP & COMMERCIALIZE PRIME EDITED EX VIVO T-CELL THERAPIES |
|
|
